Compare Biogen Inc (BIIB) vs Flux Power Holdings Inc (FLUX) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

FLUX trades at $0.7304, down 5.94% in the last session, with a bearish technical signal from moving averages. The company reported mixed quarterly results, missing Q3 2026 EPS estimates but beating in Q4 2025. Revenue declined from $66M in 2025 to $51M in 2026, with negative net income margins persisting. Recent developments include the launch of SkyEMS 3.0 AI-powered fleet management software and new executive appointments aimed at growth acceleration.

Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and ROA. The stock's primary investment opportunity lies in its clean energy technology positioning and strong analyst support, but risks include ongoing losses, revenue contraction, and competitive pressures in the energy storage market that could limit near-term upside potential.